Study guide
12.4 Obesity and Metabolic Disease
ANCC Family Nurse Practitioner FNP-BC
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 Current Exam Facts 1.2 Eligibility, Application, and Test Day 1.3 Blueprint Weights, TCO Dates, and Study Strategy
2 Assessment Foundations
2.1 Population Health Promotion and Screening 2.2 Comprehensive History and Physical 2.3 Focused History and Physical 2.4 Age-Specific Screening Schedules
3 Function, Risk, and Lifespan Assessment
3.1 Functional Assessment 3.2 Risk Assessment and Social Determinants 3.3 Pediatric Developmental Assessment 3.4 Adolescent, Adult, and Geriatric Assessment
4 Diagnosis Foundations
4.1 Pathogenesis and Pathophysiology 4.2 Diagnostic Test and Procedure Selection 4.3 Interpreting Labs and Imaging 4.4 Normal vs Abnormal Physiologic Change
5 Differential Diagnosis
5.1 Formulating Differential Diagnoses 5.2 Red Flags and Emergency Identification 5.3 Diagnostic Reasoning Traps
6 Prevention and Anticipatory Guidance
6.1 Primary, Secondary, and Tertiary Prevention 6.2 Pediatric and Adolescent Anticipatory Guidance 6.3 Adult and Geriatric Anticipatory Guidance 6.4 Immunization Planning Across the Lifespan
7 Guidelines, Culture, and Evidence
7.1 Crisis, Safety, and End-of-Life Planning 7.2 Clinical Guidelines and Standards of Care 7.3 Culturally and Ethnically Sensitive Practice 7.4 Evidence-Based Research Appraisal
8 Care Plans and Shared Decisions
8.1 Shared Decision-Making 8.2 Multimorbidity and Prioritization 8.3 Referral, Comanagement, and Transitions
9 Pharmacotherapeutics
9.1 Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics 9.2 Interactions, Contraindications, and Monitoring 9.3 Special-Population Prescribing 9.4 High-Alert Medications and Analgesic Safety
10 Cardiovascular Primary Care
10.1 Cardiovascular Diagnosis 10.2 Cardiovascular Pharmacotherapy 10.3 Nonpharmacologic Cardiovascular Management 10.4 Lifespan Cardiovascular Issues
11 Respiratory Primary Care
11.1 Respiratory Diagnosis 11.2 Respiratory Pharmacotherapy 11.3 Lifespan Respiratory Care
12 Endocrine and Metabolic Primary Care
12.1 Diabetes Diagnosis and Monitoring 12.2 Diabetes Pharmacotherapy 12.3 Thyroid and Other Endocrine Disorders 12.4 Obesity and Metabolic Disease
13 Gastrointestinal Primary Care
13.1 Gastrointestinal Diagnosis 13.2 GI Pharmacotherapy and Nutrition 13.3 Lifespan Gastrointestinal Care
14 GU, Renal, and Reproductive Primary Care
14.1 GU and Renal Diagnosis and Management 14.2 Women's Reproductive Health 14.3 Pregnancy and Postpartum Primary Care 14.4 Men's Health and Sexual Function
15 HEENT, Skin, and Musculoskeletal
15.1 HEENT Diagnosis and Management 15.2 Integumentary Diagnosis and Management 15.3 Musculoskeletal Diagnosis 15.4 MSK Procedures and Nonpharmacologic Care
16 Neuro, Psych, Heme, Immune, and Infection
16.1 Neurological Diagnosis and Management 16.2 Psychiatric Diagnosis and Substance Use 16.3 Hematopoietic and Immune Disorders 16.4 Common Infections and Anti-Infectives
17 Clinical Delivery Skills
17.1 Office Procedures and Nonpharmacologic Treatment 17.2 Patient-Specific Education 17.3 Therapeutic Communication 17.4 Comprehensive Documentation
18 Professional Practice
18.1 Legal and Ethical Implications 18.2 Health IT, EHR, and AI Ethics 18.3 Regulatory Guidelines: Reportable Disease and Abuse 18.4 APRN Scope, Standards, and FNP Role
19 Outcome Evaluation
19.1 Ethical and Legal Evaluation Issues 19.2 Pharmacotherapeutic Outcome Monitoring 19.3 Nonpharmacologic Outcome Monitoring 19.4 Clinical Data, PROs, and Treatment Efficacy
20 Follow-Up, Systems, and Exam Strategy
20.1 Follow-Up Intervals and Surveillance 20.2 Treatment Adjustment and Deprescribing 20.3 Resource Management and Care Coordination 20.4 Exam-Day Strategy and TCO Review
12.4 Obesity and Metabolic Disease
Key Takeaways Explain This Topic AI
Obesity is a chronic disease: use BMI plus waist (US abdominal obesity often >35 inches in women and >40 inches in men), not a single number or a character judgment.
Intensive lifestyle aiming at 5–10% weight loss is the base layer; it is necessary and often not sufficient.
Pharmacotherapy is indicated at BMI ≥30, or BMI ≥27 with a weight-related comorbidity; current high-yield agents are GLP-1 receptor agonists and dual GIP/GLP-1 agonists.
Typical U.S. bariatric referral thresholds are BMI ≥40, or BMI ≥35 plus a serious comorbidity — refer for evaluation, not as an FNP-performed operation.
Suspect MASLD in metabolic adults with steatosis or persistent ALT elevation; use FIB-4 conceptually and refer hepatology when it is indeterminate or high. Metabolic syndrome is a cluster — the plan is statin, blood pressure, and glucose, not the label.
Last updated: August 2026
Obesity and metabolic dysfunction–associated steatotic liver disease sit on every FNP panel. The TCO will not give you a separate obesity-chapter score, but Implementation (pharmacotherapy, referral, education) and Evaluation (weight, A1c, ALT, FIB-4) will. Treat obesity as a chronic disease , not a character flaw, and treat metabolic syndrome as a cluster of problems you actually manage , not a billing phrase that excuses ignoring the statin.
Measure more than a single BMI
BMI remains the screening number: overweight 25.0–29.9 , obesity class I 30.0–34.9 , class II 35.0–39.9 , class III ≥40 kg/m². Use ethnicity-aware judgment: many Asian adults accrue metabolic risk at lower BMI (diabetes screening often starts at BMI ≥23 in those groups). BMI under-calls risk in a central-obesity, normal-BMI adult and over-calls it in a muscular athlete.
Add waist circumference . In the United States, >35 inches (88 cm) in women and >40 inches (102 cm) in men mark abdominal obesity and raise cardiometabolic risk at any BMI. Measure standing, at the iliac crest, after a normal expiration — not a guess from the last pair of jeans.
Obesity is a disease with genetics, environment, medications (insulin, sulfonylureas, many antipsychotics, glucocorticoids, some anticonvulsants), sleep loss, and social determinants. Document it as a problem. Offer treatment the same way you offer treatment for hypertension. Shame is not a pharmacologic class.
Intensive lifestyle is still the base layer
A 5–10% weight loss improves glycemia, blood pressure, triglycerides, and steatosis. Intensive lifestyle means a calorie deficit the patient can execute , 150 minutes or more of moderate activity plus resistance work, sleep, alcohol review, and a hard look at obesogenic prescriptions. Refer to a dietitian or an intensive behavioral program when one exists. Do not prescribe eat less, move more as the entire Implementation and then blame the patient at the 3-month visit.
Lifestyle is necessary and often not sufficient. Saying try harder for six more months in a person with BMI 42, diabetes, and failed structured attempts is delay, not conservatism. Pair lifestyle with medication or a surgical referral when indications are already met.
Pharmacotherapy: who qualifies and what is high-yield in 2026
Anti-obesity pharmacotherapy is indicated at BMI ≥30 , or BMI ≥27 with a weight-related comorbidity (type 2 diabetes, hypertension, dyslipidemia, OSA, MASLD, osteoarthritis that limits activity). Current high-yield agents are GLP-1 receptor agonists (semaglutide 2.4 mg weekly for obesity) and dual GIP/GLP-1 agonists (tirzepatide), which produce the largest mean weight loss among approved primary-care options and also treat type 2 diabetes when that is on the list. Older options still exist: orlistat (GI fat malabsorption; fat-soluble vitamin counseling), phentermine (short-term sympathomimetic; avoid in uncontrolled hypertension and CAD), phentermine/topiramate, and naltrexone/bupropion (avoid in uncontrolled hypertension and in patients on opioids).
Counsel the same GI titration, gallbladder, and thyroid C-cell / MEN2 boxed-warning story you already know from section 12.2. These drugs are chronic therapy ; weight usually returns when they stop. Do not present them as a 12-week jump start. Review contraception — rapidly changing weight and some combinations affect pregnancy planning, and some agents are teratogenic. Stop or switch if there is no meaningful response after an adequate trial at a tolerated dose — do not escalate forever on a nonresponder.
Cost, supply, and compounding-pharmacy substitutes are real clinic problems. The exam still wants the indication , the comorbidity threshold , and the safety counseling , not a copay.
Bariatric surgery referral — typical U.S. criteria
State these as typical U.S. referral thresholds , not as a law of nature: refer for evaluation when BMI ≥40 , or BMI ≥35 with a serious comorbidity (type 2 diabetes, OSA, poorly controlled hypertension, MASLD with fibrosis concern). Some metabolic-surgery pathways now consider lower BMI in selected type 2 diabetes; if the stem is a classic primary-care item, the 40 / 35-plus-comorbidity pair is the expected answer. Referral is for evaluation , not an FNP-performed bypass. Preoperative work includes glycemic optimization, smoking cessation, nutrition, and a mental-health screen. Postoperative primary care watches dumping, micronutrients (B12, iron, vitamin D, calcium, thiamine), pregnancy timing, and the sudden drop in insulin or sulfonylurea requirement — hypoglycemia is an early postoperative trap.
MASLD (formerly NAFLD): suspect, score, refer
Metabolic dysfunction–associated steatotic liver disease (MASLD) , formerly NAFLD, is hepatic steatosis with cardiometabolic risk and little or no alcohol. Suspect it when type 2 diabetes, obesity, mixed hyperlipidemia, or a persistent mild-to-moderate ALT elevation appears, or when ultrasound already said fatty liver. History must quantify alcohol so you do not miss alcohol-associated liver disease.
FIB-4 is the primary-care fibrosis screen: it uses age, AST, ALT, and platelet count . A low FIB-4 makes advanced fibrosis unlikely — stay in primary care, treat weight, glucose, lipids, and alcohol, and repeat periodically. An indeterminate or high FIB-4 needs elastography or hepatology referral , not another 3 years of watch the ALT. Refer also for ALT that keeps rising, jaundice, low albumin, high INR, thrombocytopenia, or uncertainty about the diagnosis.
Treatment of MASLD in primary care is weight loss (7–10%) , glycemic and lipid control , alcohol minimization , and — when diabetes is present — agents with liver or weight benefit (GLP-1 RA / dual agonists; pioglitazone in selected patients without heart failure). Specialty drugs for MASH with fibrosis exist and belong with hepatology. Do not prescribe herbal liver cleanses.
Metabolic syndrome is a cluster, not a plan
Metabolic syndrome is commonly three of five : elevated waist, elevated triglycerides, low HDL, elevated blood pressure, and elevated fasting glucose (or treated hypertension or treated hyperglycemia, depending on the definition you were taught). Naming the syndrome does not replace treating the pieces.
Component The actual FNP plan
Atherogenic lipids Statin when 10-year ASCVD risk, diabetes age 40–75, or LDL-C threshold says so — not diet only because you wrote metabolic syndrome
- Blood pressure Lifestyle plus antihypertensives to target; ACE/ARB if albuminuria or diabetes with CKD
- Glucose Prediabetes lifestyle plus metformin in selected adults; diabetes regimen from section 12.2
- Waist / weight Intensive lifestyle plus obesity pharmacotherapy plus bariatric referral when indicated
- Prothrombotic and inflammatory milieu Smoking cessation, activity, sleep-apnea evaluation
Do not skip an indicated high-intensity statin in a 58-year-old with diabetes and an LDL-C of 142 because we are focusing on weight this year. Do not ignore a blood pressure of 154/92 because the GLP-1 RA might fix it later.
Vignette. A 52-year-old with BMI 36, waist 44 inches, triglycerides 240 mg/dL, HDL 36 mg/dL, BP 148/90, fasting glucose 118 mg/dL, and an ALT of 62 has obesity, prediabetes, and probable MASLD. Calculate FIB-4. Offer intensive lifestyle and discuss obesity pharmacotherapy (BMI ≥30). Treat blood pressure now. Discuss a statin using a formal risk calculation, not a vibe. Repeat glucose testing because 118 mg/dL is prediabetes, not a free pass. That is the plan. Metabolic syndrome — return in 1 year is not.
A second common stem is the 47-year-old with BMI 27.4, treated hypertension, and OSA who asks about an injection for weight. That person meets the ≥27-plus-comorbidity pharmacotherapy threshold even though BMI is not 30. A third is the 44-year-old with BMI 41 and no other diagnosis: bariatric referral is already on the table alongside lifestyle and medication, not after another undocumented decade of trying.
Evaluation is weight trend, waist, A1c or fasting glucose, blood pressure, lipids, FIB-4 or ALT trajectory, and medication adverse effects. If the needle does not move, change the intensity of the intervention — do not write a longer lecture.